Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TheraCour-HSV2
- Development stage
- Preclinical
- Lead developer
- NanoViricides
- Modality
- Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Topical
01
Overview
TheraCour-HSV2 is a preclinical nanomedicine candidate developed by NanoViricides, under license from AllExcel and TheraCour Pharma, for the treatment of genital ulcers caused by Herpes Simplex Virus Type 2 (HSV-2). The drug utilizes the proprietary TheraCour polymeric micelle platform to create "nanoviricides"—biomimetic nanostructures designed to identify and neutralize specific viruses. These micelles are engineered to display ligands that mimic the host cell receptors used by HSV-2 for entry, such as heparan sulfate. Upon binding to the virus, the flexible polymeric shell of the micelle is thought to wrap around and engulf the viral particle, potentially dismantling the viral envelope and preventing the infection of healthy cells. The candidate is currently in preclinical development, with the goal of providing a topical treatment for genital herpes outbreaks.
- Brand names
- HerpeCide
- Other names
- TheraCour-HSV2-NanoViricidesTheraCour-HSV-2-NanoViricidesTheraCour-HSV 2-NanoViricidesNanoViricides HSV-2 candidate
02
Targets
HSV-2 gC/gD/gE (Herpes simplex virus type 2 glycoproteins C/D/E)
Beyond the preview
Go deeper on TheraCour-HSV2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TheraCour-HSV2.